Company Overview and News

 
NGEX REPORTS FIRST QUARTER 2018 RESULTS

2018-05-10 globenewswire
Vancouver, May 09, 2018 (GLOBE NEWSWIRE) -- NGEx Resources Inc. (TSX: NGQ) (OMX: NGQ) (“NGEx” or the “Company”) is pleased to announce its results for the three months ended March 31, 2018.

 
NGEx Provides Update on Exploration Program at Nacimientos Project, Argentina

2018-04-23 globenewswire
NGEx Resources Inc. (TSX: NGQ) (Nasdaq Stockholm: NGQ) (“NGEx” or the “Company”) is pleased to report that it has started a three to four hole scout drilling program at its new Nacimientos copper/gold project located in San Juan Province, Argentina. This first pass program is designed to test some of the ideas and targets generated earlier this season before the onset of the southern hemisphere winter.

 
NGEx Provides Update on Exploration Program at Nacimientos Project, Argentina

2018-04-23 globenewswire
VANCOUVER, British Columbia, April 23, 2018 (GLOBE NEWSWIRE) -- NGEx Resources Inc. (TSX:NGQ) (Nasdaq Stockholm:NGQ) (“NGEx” or the “Company”) is pleased to report that it has started a three to four hole scout drilling program at its new Nacimientos copper/gold project located in San Juan Province, Argentina. This first pass program is designed to test some of the ideas and targets generated earlier this season before the onset of the southern hemisphere winter.

 
NGEx Share Capital and Voting Rights Update

2018-03-29 globenewswire
Vancouver, March 29, 2018 (GLOBE NEWSWIRE) -- NGEx Resources Inc. ("NGEx" or the “Company”) (TSX: NGQ; NASDAQ Stockholm: NGQ), reports the following share capital and voting rights update in accordance with the Swedish Financial Instruments Trading Act.

 
NGEx Share Capital and Voting Rights Update

2018-03-29 globenewswire
VANCOUVER, British Columbia, March 29, 2018 (GLOBE NEWSWIRE) -- NGEx Resources Inc. ("NGEx" or the “Company”) (TSX:NGQ) (NASDAQ Stockholm:NGQ), reports the following share capital and voting rights update in accordance with the Swedish Financial Instruments Trading Act.

 
NGEx Reports 2017 Results

2018-02-22 marketwired
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 21, 2018) - NGEx Resources Inc. (TSX:NGQ)(OMX:NGQ) ("NGEx" or the "Company") is pleased to announce its results for the year ended December 31, 2017.

 
Zebra Holdings and Investments S.a.r.l. Acquires Shares of NGEx Resources Inc.

2018-02-02 marketwired
LUXEMBOURG, LUXEMBOURG--(Marketwired - Feb. 1, 2018) - Zebra Holdings and Investments S.à.r.l. ("Zebra"), a company controlled by a trust settled by the late Adolf H. Lundin, incorporated under the laws of Luxembourg, 40, Boulevard Grande Duchesse Charlotte, L-1330 Luxembourg, announced today that it had acquired 16,300,000 common shares of NGEx Resources Inc. ("NGEx" or the "Company") (TSX VENTURE:NGQ)(NASDAQ OMX:NGQ) for Cdn$ 1.

 
NGEx Share Capital and Voting Rights Update

2018-01-31 marketwired
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 31, 2018) - NGEx Resources Inc. ("NGEx" or the "Company") (TSX:NGQ)(NASDAQ OMX:NGQ), reports the following share capital and voting rights update in accordance with the Swedish Financial Instruments Trading Act.

1
NGEx Closes CDN $12.5 Million Private Placement

2018-01-03 marketwired
NGEx Resources Inc. (TSX:NGQ)(NASDAQ OMX:NGQ) ("NGEx" or the "Company") is pleased to report that it has closed its previously announced private placement.

 
NGEx Announces Increase in Private Placement to Cdn $12.5 Million

2017-12-15 marketwired
NGEx Resources Inc. (TSX:NGQ)(NASDAQ OMX:NGQ) ("NGEx" or the "Company") is pleased to announce that due to strong demand, the Company will increase the non-brokered, private placement announced on December 14, 2017 from Cdn $10 million to Cdn $12.5 million The Company will now sell an aggregate of up to 12.5 million common shares (the "Common Shares") at a price of $1.00 per Common Share for gross proceeds of up to Cdn $12.

 
BRIEF-NGEx Announces CDN $10 Million Private Placement

2017-12-14 reuters
* NGEX RESOURCES - INTENDS TO SELL ON A NON-BROKERED, PRIVATE PLACEMENT BASIS, AN AGGREGATE OF UP TO 10 MILLION COMMON SHARES AT $1.00/COMMON SHARE

 
NGEx Announces Cdn $10 Million Private Placement

2017-12-14 marketwired
NGEx Resources Inc. (TSX:NGQ)(NASDAQ OMX:NGQ) ("NGEx" or the "Company") is pleased to announce that it intends to sell on a non-brokered, private placement basis, an aggregate of up to 10 million common shares (the "Common Shares") at a price of $1.00 per Common Share for gross proceeds of up to Cdn $10 million (the "Private Placement").

 
Golden Arrow Resources: Undervalued With Catalysts

2017-12-04 seekingalpha
Golden Arrow's Puna Operations Inc. joint venture with SSR Mining will likely obtain its necessary permits this month.

1
NGEx Share Capital and Voting Rights Update

2017-11-30 marketwired
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 30, 2017) - NGEx Resources Inc. ("NGEx" or the "Company") (TSX:NGQ)(NASDAQ OMX:NGQ), reports the following share capital and voting rights update in accordance with the Swedish Financial Instruments Trading Act.

 
Filo Mining Reports Third Quarter 2017 Results

2017-11-28 marketwired
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 28, 2017) - Filo Mining Corporation (TSX VENTURE:FIL)(OMX:FIL) ("Filo Mining" or the "Company") is pleased to announce its results for the three and nine months ended September 30, 2017.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...